Biotica discovers and develops novel polyketide therapeutics to create new medicines for serious diseases. Biotica’s R&D pipeline is focused on optimised polyketide therapeutics for high-value indications. Biotica's compounds, generated using the proprietary novoPT™ technology, have unique chemistry and differentiated properties. Polyketides are the basis of more than 40 successful therapeutics in a wide range of diseases. They make excellent leads for drug discovery, with naturally high affinity to biologically relevant targets, including protein-protein interactions and other traditionally difficult targets. Biotica has formed successful partnerships with leading pharmaceutical companies, most recently Wyeth and GSK, based on its high-value projects. Projects are selected on three key criteria: market potential, clinical validation of the target and Biotica exclusivity.